• JPD200_slider_2



Our (e)Books and (e)Journals

IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.

  • IOS_30_Logo_11716_FINAL2
  • go-to-ejournals
  • kudos_static_310_x_62
  • Rehab Journals
  • Neuro Journals
  • Go to IOS Press Ebooks
  • Millpress and Delft University Press imprints IOS Press
  • Statement side banner



When artificial intelligence evaluates chess champions

April 25, 2017 - The ELO system, which most chess federations use today, ranks players by the results of their games. Although simple and efficient, it overlooks relevant criteria such as the quality of the moves players actually make. To overcome these limitations, Jean-Marc Alliot of the Institut de recherche en informatique de Toulouse (IRIT - CNRS/INP Toulouse/Université Toulouse Paul Sabatier/Université Toulouse Jean Jaurès/Université Toulouse Capitole) demonstrates a new system, published on 24 april 2017 in the ICGA Journal (International Computer Games Association) .

April 25, 2017

Detecting Alzheimer’s disease earlier using … Greebles?

April 15, 2017 - LOUISVILLE, Ky. – Unique graphic characters called Greebles may prove to be valuable tools in detecting signs of Alzheimer’s disease decades before symptoms become apparent.

April 15, 2017

IOS Press Celebrates 30th Anniversary

April 7, 2017 - Amsterdam, The Netherlands, 7 April 2017 – IOS Press, publisher of scientific, technical and medical books and journals, celebrates its 30th anniversary this week. Friends and colleagues came together on the 4th of April for a mini-symposium in Amsterdam venue De Balie to commemorate this special event. The rest of the week was filled with social events and meetings with IOS Press’s collaborators.

April 7, 2017

3D Signatures’s TeloViewTM Software Identifies and Stages Patients with Alzheimer’s Disease from a Cheek Swab

March 30, 2017 - WINNIPEG, MB − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the "Company" or "3DS"), is pleased to announce clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloViewTM software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.

March 30, 2017